New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas

Relevance. Cutaneous T-cell lymphomas (CTCL) are not common diseases which are associated with a decrease in quality of life. Currently available systemic therapy rarely provides a stable and long-termed response. In Russia, current CTCL therapy is a big issue due to the limited access to modern tar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Irina V. Poddubnaya, Vadim V. Ptushkin, Irena E. Belousova, L. G. Gorenkova, Kamil D. Kaplanov, A. E. Karamova, Alla M. Kovrigina, O. A. Kolomeitsev, T. S. Konstantinova, Muza M. Kokhan, Tatyana I. Pospelova
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	brentuximab vedotin cd30 + primary cutaneous t-cell lymphoma mycosis fungoides sézary syndrome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f921cc1b2d574f329683c8677d437862
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f921cc1b2d574f329683c8677d437862
record_format	dspace
spelling	oai:doaj.org-article:f921cc1b2d574f329683c8677d4378622021-11-30T17:03:34ZNew opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas1815-14341815-144210.26442/18151434.2020.2.200205https://doaj.org/article/f921cc1b2d574f329683c8677d4378622020-07-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/34929/23348https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Relevance. Cutaneous T-cell lymphomas (CTCL) are not common diseases which are associated with a decrease in quality of life. Currently available systemic therapy rarely provides a stable and long-termed response. In Russia, current CTCL therapy is a big issue due to the limited access to modern targeted therapy, an absence of a National CTCL registry, and the difficulties in morphological diagnosis of these rare diseases. Since June 17, 2019, a new indication of brentuximab vedotin as a new treatment option for patients with CD30+ CTCL after at least one line of previous systemic therapy was registered. Brentuximab vedotin is a conjugate of a CD30 directed monoclonal antibody and an antitumor agent. Brentuximab vedotin is a CD30-directed monoclonal antibody conjugated to an antitumor agent. Aim. To identify the unresolved issues of current clinical practice and to adapt available approaches to the treatment and diagnosis of CD30 + CTCL given new therapeutic opportunities. Results. The available approaches to the systemic CTCL therapy in Russia routine clinical practice have been discussed, the unresolved issues of therapy and diagnosis have been identified, the routing of patients with CD30 + CTCL in Russia has been discussed, the importance of CD30 testing has been established, the profiles of patients with CTCL for treatment with brentuximab vedotin have been determined.Irina V. PoddubnayaVadim V. PtushkinIrena E. BelousovaL. G. GorenkovaKamil D. KaplanovA. E. KaramovaAlla M. KovriginaO. A. KolomeitsevT. S. KonstantinovaMuza M. KokhanTatyana I. PospelovaIP Habib O.N.articlebrentuximab vedotincd30 + primary cutaneous t-cell lymphomamycosis fungoidessézary syndromeNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 2, Pp 79-81 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	brentuximab vedotin cd30 + primary cutaneous t-cell lymphoma mycosis fungoides sézary syndrome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	brentuximab vedotin cd30 + primary cutaneous t-cell lymphoma mycosis fungoides sézary syndrome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Irina V. Poddubnaya Vadim V. Ptushkin Irena E. Belousova L. G. Gorenkova Kamil D. Kaplanov A. E. Karamova Alla M. Kovrigina O. A. Kolomeitsev T. S. Konstantinova Muza M. Kokhan Tatyana I. Pospelova New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
description	Relevance. Cutaneous T-cell lymphomas (CTCL) are not common diseases which are associated with a decrease in quality of life. Currently available systemic therapy rarely provides a stable and long-termed response. In Russia, current CTCL therapy is a big issue due to the limited access to modern targeted therapy, an absence of a National CTCL registry, and the difficulties in morphological diagnosis of these rare diseases. Since June 17, 2019, a new indication of brentuximab vedotin as a new treatment option for patients with CD30+ CTCL after at least one line of previous systemic therapy was registered. Brentuximab vedotin is a conjugate of a CD30 directed monoclonal antibody and an antitumor agent. Brentuximab vedotin is a CD30-directed monoclonal antibody conjugated to an antitumor agent. Aim. To identify the unresolved issues of current clinical practice and to adapt available approaches to the treatment and diagnosis of CD30 + CTCL given new therapeutic opportunities. Results. The available approaches to the systemic CTCL therapy in Russia routine clinical practice have been discussed, the unresolved issues of therapy and diagnosis have been identified, the routing of patients with CD30 + CTCL in Russia has been discussed, the importance of CD30 testing has been established, the profiles of patients with CTCL for treatment with brentuximab vedotin have been determined.
format	article
author	Irina V. Poddubnaya Vadim V. Ptushkin Irena E. Belousova L. G. Gorenkova Kamil D. Kaplanov A. E. Karamova Alla M. Kovrigina O. A. Kolomeitsev T. S. Konstantinova Muza M. Kokhan Tatyana I. Pospelova
author_facet	Irina V. Poddubnaya Vadim V. Ptushkin Irena E. Belousova L. G. Gorenkova Kamil D. Kaplanov A. E. Karamova Alla M. Kovrigina O. A. Kolomeitsev T. S. Konstantinova Muza M. Kokhan Tatyana I. Pospelova
author_sort	Irina V. Poddubnaya
title	New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
title_short	New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
title_full	New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
title_fullStr	New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
title_full_unstemmed	New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
title_sort	new opportunities of systemic therapy of cd30-positive primary cutaneous t-cell lymphomas
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/f921cc1b2d574f329683c8677d437862
work_keys_str_mv	AT irinavpoddubnaya newopportunitiesofsystemictherapyofcd30positiveprimarycutaneoustcelllymphomas AT vadimvptushkin newopportunitiesofsystemictherapyofcd30positiveprimarycutaneoustcelllymphomas AT irenaebelousova newopportunitiesofsystemictherapyofcd30positiveprimarycutaneoustcelllymphomas AT lggorenkova newopportunitiesofsystemictherapyofcd30positiveprimarycutaneoustcelllymphomas AT kamildkaplanov newopportunitiesofsystemictherapyofcd30positiveprimarycutaneoustcelllymphomas AT aekaramova newopportunitiesofsystemictherapyofcd30positiveprimarycutaneoustcelllymphomas AT allamkovrigina newopportunitiesofsystemictherapyofcd30positiveprimarycutaneoustcelllymphomas AT oakolomeitsev newopportunitiesofsystemictherapyofcd30positiveprimarycutaneoustcelllymphomas AT tskonstantinova newopportunitiesofsystemictherapyofcd30positiveprimarycutaneoustcelllymphomas AT muzamkokhan newopportunitiesofsystemictherapyofcd30positiveprimarycutaneoustcelllymphomas AT tatyanaipospelova newopportunitiesofsystemictherapyofcd30positiveprimarycutaneoustcelllymphomas
_version_	1718406420783693824

New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas

Ejemplares similares